CYC vs TRI

ASX Healthcare sector comparison — updated 14 Jul 2026 — Healthcare sector

CYC

CYCLOPHARM FPO [CYC]

41LOW

TRI

TRIVARX FPO [TRI]

51MEDIUM

Score Breakdown

CYC TRI
Technical
41
32
Catalyst
51
50
Sentiment
50
50
Fundamental
69
55
Momentum
39
67
Risk Gate
50
35

Key Metrics

CYC Metric TRI
$61.6MMarket Cap$20.8M
345KAvg Volume (20d)547K
N/AShort InterestN/A
$1.29052-Week High$0.035
$0.45052-Week Low$0.008
-6.7%Daily Change+0.0%
$0.490Reference Price$0.018
-49.3%ROE-12.1%
-53.3%Profit MarginN/A

Active Signals

CYC Signals

●RSI drifting toward oversold territory — worth watching
●Volume surging at 2.7x normal while price falls — heavy selling pressure
●Watch out — volume is flowing out even as price holds up. Distribution pattern
●Below the 200-day average — the long-term trend is still working against it
●Critical cash runway (1.5 quarters)
●Low P/S ratio (1.9x)
●Moderate revenue growth (+10%)
●EPS estimates revised upward (+10pts)

TRI Signals

●RSI drifting toward oversold territory — worth watching
●MACD momentum is losing steam
●Stochastic is deep in oversold territory — bounce conditions forming
●Trading below both moving averages — the trend is working against this one
●Sitting near support — this level has held before and could attract buyers again
●Took a hit — down 10.0% over the last 5 days
●Lagging the Small Ords index — relative strength of 0.84, underperforming its peers
●Below the 200-day average — the long-term trend is still working against it

Ask Scout AI to compare CYC and TRI in depth.

Open Scout AI →

Track both stocks and 2,200+ more — Free

Daily AI-powered screening across every ASX small cap.

Open Screener

Related Comparisons

DXB vs ENL →DXB vs EZZ →DXB vs HIQ →DXB vs ILA →DXB vs MSB →
CYC Full Analysis → TRI Full Analysis → Healthcare Sector → All Comparisons →
GENERAL INFORMATION ONLY. SmallCapData provides algorithmic screening data and does not constitute personal financial advice, a recommendation, or an offer to buy or sell any security. This content is produced by an algorithm, not a licensed financial adviser. You should consider seeking independent financial advice before making any investment decision. Past performance is not indicative of future results. Trading in small-cap securities carries a high degree of risk, including the risk of total loss of capital. The author may hold positions in mentioned securities. SmallCapData does not hold an Australian Financial Services Licence (AFSL).